BioCryst Pharmaceuticals, Inc. (BCRX) Reports In-Line Q1 Loss; Offers Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
BioCryst Reports First Quarter 2014 Financial Results
May 8, 2014 6:51 AM EDTRESEARCH TRIANGLE PARK, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the first quarter ended March 31, 2014.
"We have completed enrollment in the OPuS-1 Phase 2 trial to evaluate orally-administered BCX4161 in patients with hereditary... More
